Clinical Trial: An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
Study Status: ACTIVE_NOT_RECRUITING
Recruit Status: ACTIVE_NOT_RECRUITING
Condition: Metastatic Colorectal Cancer (mCRC)
Study Type: OBSERVATIONAL
Official Title: (STAR-T) Sequential TreAtment With Regorafenib and Trifluridine/Tipiracil (TAS-102, With or Without Bevacizumab) in Refractory Metastatic Colorectal Cancer: Real-world Outcomes in Community Clini
Brief Summary:
This is an observational study using data that has been collected from participants who received their usual treatments.Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part of the bowel just before the anus) that has spread to other parts of the body.Regorafenib is an anti-cancer drug that blocks several proteins, called enzymes, which are involved in the growth of cancer.The combination of anti-cancer drugs trifluridine and tipiracil is called TAS-102.It prevents…
Read more